Class of 2016


Oncolinx, in conjunction with the National Cancer Institute is developing the next generation of targeted cancer therapies: antibody-drug conjugates (ADCs). Oncolinx ADCs carry a patented, immune-activating drug payload called the Azonafide directly, and exclusively, to cancer cells, and not healthy cells, thereby avoiding many of the adverse side-effects of chemotherapy.

The Oncolinx platform is partnered with more than 14 leading pharmaceutical companies and 6 academic labs all over the world— concurrently developing ADCs across 30 different cancer indications. Oncolinx aims to enter clinical trials with a partnered program in mid-2017.



Riley Ennis
Sourav Sinha


In three words describe your team

Riley Ennis: Contrarian, empathetic, and data-driven.

What's your why? (Why did you create this company?)

RE: To improve overall survival and minimize drug side effects for cancer patients.

What is the most exciting thing about being an entrepreneur?

RE: Working with people who love what they do and are passionate about a shared vision.